History and progress of hypotheses and clinical trials for Alzheimer’s disease

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its main pathological features are cerebral atrophy, amyloid plaques, and neurofibrillary tangles in the brains of patients. There are various descriptive hypotheses regarding the causes of AD, including the cholinergic hypothesis, amyloid hypothesis, tau propagation hypothesis, mitochondrial cascade hypothesis, calcium homeostasis hypothesis, neurovascular hypothesis, inflammatory hypothesis, metal ion hypothesis, and lymphatic system hypothesis. However, the ultimate etiology of AD remains obscure. In this review, we discuss the main hypotheses of AD and related clinical trials. Wealthy puzzles and lessons have made it possible to develop explanatory theories and identify potential strategies for therapeutic interventions for AD. The combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD. We further propose that fluoxetine, a selective serotonin reuptake inhibitor, has the potential to treat AD.

Cited by papers we hold 17

• Mitochondrial dysfunction: mechanisms and advances in therapy · 2024
  No notice
• Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies · 2024
  No notice
• Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases · 2024
  No notice
• Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks · 2023
  No notice
• TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases · 2023
  No notice
• A Bibliometric Review on Gut Microbiome and Alzheimer’s Disease Between 2012 and 2021 · 2022
  Not checked
• Role of Cholinergic Signaling in Alzheimer’s Disease · 2022
  No notice
• A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics · 2022
  No notice
• Alzheimer’s Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer’s Disease and Type 2 Diabetes · 2022
  No notice
• Periodontal microorganisms and Alzheimer disease – A causative relationship? · 2022
  No notice
• Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier · 2021
  No notice
• Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery · 2021
  No notice
• Alzheimer’s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia · 2021
  No notice
• Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis · 2021
  No notice
• The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain · 2021
  No notice
• Neuroprotective Natural Products for Alzheimer’s Disease · 2021
  No notice
• Alterations in resting-state network dynamics along the Alzheimer’s disease continuum · 2020
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.